BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brasil S, Pascoal C, Francisco R, Dos Reis Ferreira V, Videira PA, Valadão AG. Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter? Genes (Basel) 2019;10:E978. [PMID: 31783696 DOI: 10.3390/genes10120978] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Ali SR, Bryce J, Tan LE, Hiort O, Pereira AM, van den Akker ELT, Appelman-Dijkstra NM, Bertherat J, Cools M, Dekkers OM, Kodra Y, Persani L, Smyth A, Smythe C, Taruscio D, Ahmed SF. The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. Int J Environ Res Public Health 2020;17:E8743. [PMID: 33255540 DOI: 10.3390/ijerph17238743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bozhko DV, Myrov VO, Kolchanova SM, Polovian AI, Galumov GK, Demin KA, Zabegalov KN, Strekalova T, de Abreu MS, Petersen EV, Kalueff AV. Artificial intelligence-driven phenotyping of zebrafish psychoactive drug responses. Prog Neuropsychopharmacol Biol Psychiatry 2021;112:110405. [PMID: 34320403 DOI: 10.1016/j.pnpbp.2021.110405] [Reference Citation Analysis]
3 Brasil S, Neves CJ, Rijoff T, Falcão M, Valadão G, Videira PA, Dos Reis Ferreira V. Artificial Intelligence in Epigenetic Studies: Shedding Light on Rare Diseases. Front Mol Biosci 2021;8:648012. [PMID: 34026829 DOI: 10.3389/fmolb.2021.648012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Faviez C, Chen X, Garcelon N, Neuraz A, Knebelmann B, Salomon R, Lyonnet S, Saunier S, Burgun A. Diagnosis support systems for rare diseases: a scoping review. Orphanet J Rare Dis 2020;15:94. [PMID: 32299466 DOI: 10.1186/s13023-020-01374-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
5 Challa AP, Zaleski NM, Jerome RN, Lavieri RR, Shirey-Rice JK, Barnado A, Lindsell CJ, Aronoff DM, Crofford LJ, Harris RC, Alp Ikizler T, Mayer IA, Holroyd KJ, Pulley JM. Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. Front Genet 2021;12:707836. [PMID: 34394194 DOI: 10.3389/fgene.2021.707836] [Reference Citation Analysis]
6 Solomon BD. Can artificial intelligence save medical genetics? Am J Med Genet A 2021. [PMID: 34633139 DOI: 10.1002/ajmg.a.62538] [Reference Citation Analysis]
7 Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug Repurposing for Rare Diseases. Trends Pharmacol Sci 2021;42:255-67. [PMID: 33563480 DOI: 10.1016/j.tips.2021.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
8 Schaefer J, Lehne M, Schepers J, Prasser F, Thun S. The use of machine learning in rare diseases: a scoping review. Orphanet J Rare Dis. 2020;15:145. [PMID: 32517778 DOI: 10.1186/s13023-020-01424-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
9 Rubinstein YR, Robinson PN, Gahl WA, Avillach P, Baynam G, Cederroth H, Goodwin RM, Groft SC, Hansson MG, Harris NL, Huser V, Mascalzoni D, McMurry JA, Might M, Nellaker C, Mons B, Paltoo DN, Pevsner J, Posada M, Rockett-Frase AP, Roos M, Rubinstein TB, Taruscio D, van Enckevort E, Haendel MA. The case for open science: rare diseases. JAMIA Open 2020;3:472-86. [PMID: 33426479 DOI: 10.1093/jamiaopen/ooaa030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Andrade-Campos MM, de Frutos LL, Cebolla JJ, Serrano-Gonzalo I, Medrano-Engay B, Roca-Espiau M, Gomez-Barrera B, Pérez-Heredia J, Iniguez D, Giraldo P. Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis 2020;15:256. [PMID: 32962737 DOI: 10.1186/s13023-020-01520-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Decherchi S, Pedrini E, Mordenti M, Cavalli A, Sangiorgi L. Opportunities and Challenges for Machine Learning in Rare Diseases. Front Med (Lausanne) 2021;8:747612. [PMID: 34676229 DOI: 10.3389/fmed.2021.747612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moor CC, Kreuter M, Luppi F, Wuyts WA. The world is not enough - the value of increasing registry data in idiopathic pulmonary fibrosis. Respir Res 2020;21:105. [PMID: 32375778 DOI: 10.1186/s12931-020-01377-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Klumpp M, Hintze M, Immonen M, Ródenas-Rigla F, Pilati F, Aparicio-Martínez F, Çelebi D, Liebig T, Jirstrand M, Urbann O, Hedman M, Lipponen JA, Bicciato S, Radan AP, Valdivieso B, Thronicke W, Gunopulos D, Delgado-Gonzalo R. Artificial Intelligence for Hospital Health Care: Application Cases and Answers to Challenges in European Hospitals. Healthcare (Basel) 2021;9:961. [PMID: 34442098 DOI: 10.3390/healthcare9080961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020;45:87. [PMID: 32661214 [PMID: 32661214 DOI: 10.1007/s12038-020-00067-w] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 35.0] [Reference Citation Analysis]